Breaking News

bioRASI Acquires Sponsors Clinical Research Group

March 27, 2013

Expands Eastern European presence

bioRASI has acquired Sponsors Clinical Research Group, LLC (SCRG), a Ukrainian based regulatory and clinical CRO. SCRG, established in 2004, conducts clinical studies in a range of therapeutic areas, including cardiology, neurology, oncology, endocrinology and pulmonology.
 
"We have been working with SCRG for over a year and have been impressed with the superior expertise of its staff, so it was only natural to consider a more integrated structure," said Dr. Boris Reznik, chairman of bioRASI. "This acquisition enhances bioRASI's global infrastructure focused on delivering optimized clinical development for our sponsors who are under increasing pressure to accelerate drug development timelines while minimizing costs." 
 
"While SCRG has been working for many global sponsors and CROs, we have never experienced the powers of project management comparable to that of bioRASI," said Dr. Veklych, SCRG's executive director. "An integrated set of tools embodied in the bioRASI Process Infrastructure (BPI) greatly enhances optimized project delivery capabilities. We are excited about being a part of bioRASI's winning team."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important